Evidence map›Paper›PMID 41272205›Full record

ArticleScientific reports2025

Bioinformatics analysis to explore the potential prognostic utility of hsa-miR-103a-3p in head and neck squamous cell carcinoma.

Hanin Shoukry, Aliaa A Elsherbiny, Sally A Fahim

Abstract read
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Tropical medicine and infectious disease · 2026
    Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Hanin ShoukrySchool of Pharmacy, New Giza University (NGU), Newgiza University (NGU), km 22 Cairo-Alexandria Desert Road, P.O. Box 12577, Giza, Egypt.
Aliaa A ElsherbinyDepartment of Biochemistry, School of Pharmacy, Newgiza University (NGU), Newgiza, km 22 Cairo-Alexandria Desert Road, P.O. Box 12577, Giza, Egypt.
Sally A FahimDepartment of Biochemistry, School of Pharmacy, Newgiza University (NGU), Newgiza, km 22 Cairo-Alexandria Desert Road, P.O. Box 12577, Giza, Egypt. sally.atef@ngu.edu.eg.ORCID http://orcid.org/0000-0002-7934-5030

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Head and neck squamous cell carcinoma (HNSCC), the seventh most common cancer globally, has not yet seen an exploration of the specific role of hsa-miR-103a-3p. This study employs integrated bioinformatics analysis to investigate the function, regulatory patterns, and prognostic significance of hsa-miR-103a-3p in HNSCC. The Kaplan-Meier database was used for pan-cancer prognostic analysis of hsa-miR-103a-3p. Expression significance was assessed using the dbDEMC and GSE124566 dataset from GEO. TargetScan, RNA22, miRDB, and miRWalk identified potential targets, while GEPIA 2.0 provided differentially expressed genes (DEGs). Functional and pathway enrichment analyses were conducted using ShinyGO and KOBAS. Elevated hsa-miR-103a-3p expression correlated with poor overall survival and was upregulated in HNSCC tissues. Integration of four target prediction tools yielded 297 candidate genes. Among them, HOXD10, HMGA2, and THY1 showed the highest expression, whereas UBL3, AMOT, and PDK4 displayed low levels. UBE2Q1, ZFPM2, and ATXN1 demonstrated the strongest accessibility to hsa-miR-103a-3p binding. Network analysis revealed interactions with transcription factors and tumor-related genes, while enrichment highlighted involvement in upstream regulators and downstream cancer-associated pathways. This study identified 297 target genes and clarified the regulatory role of hsa-miR-103a-3p through interaction networks, transcription factor associations, and pathway enrichment. These findings suggest a potential oncogenic role for hsa-miR-103a-3p in modulating the cAMP signaling pathway, proteoglycans in cancer, and related mechanisms, thereby linking its molecular regulation to poor prognosis and potential therapeutic targeting in HNSCC.

Indexed as

Computational BiologyHead and Neck NeoplasmsMicroRNAsSquamous Cell Carcinoma of Head and NeckBiomarkers, TumorGene Expression ProfilingGene Expression Regulation, NeoplasticGene Regulatory NetworksHumansKaplan-Meier EstimatePrognosisBiomarkers, TumorMicroRNAsMIRN103 microRNA, humanBioinformaticsGene ontologyHNSCChsa-miR-103a-3pTarget genes

Identifiers

PMID41272205
PMCPMC12639060

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.